Signia Therapeutics is a spin-off of the VirPath Lab (University Claude Bernard Lyon 1, Lyon, France). Signia Therapeutics proposes an innovative and versatile platform for antiviral drug discovery and repositioning based on globally targeting the host cell instead of specific viral molecular determinants. The Company’s strategy is well adapted to the pathogenesis of respiratory acute infections and provides a novel approach for the identification of broad-spectrum effective antivirals. The innovative and proprietary platform will offer the minimization of drug resistance, with significant regulatory and financial benefits compared to the time-consuming and costly process of classical de novo molecule development.
Signia Therapeutics was laureate of the i-Lab 2017 award from the French Ministry of Higher Education, Research and Innovation, and BpiFrance. The company has also been awarded the EIC Accelerator by the EU H2020 Framework Programme for Research and Innovation in 2020.